BENSALEM, Pa.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24BSX&src=ctag” target=”_blank”gt;$BSXlt;/agt; lt;a href=”https://twitter.com/hashtag/classaction?src=hash” target=”_blank”gt;#classactionlt;/agt;–Law Offices of Howard G. Smith reminds investors of the upcoming June
24, 2019 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors who purchased Boston Scientific
Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX)
securities between February 26, 2015 and April 16, 2019,
inclusive (the “Class Period”).
Investors suffering losses on their Boston Scientific investments are
encouraged to contact the Law Offices of Howard G. Smith to discuss
their legal rights in this class action at 888-638-4847 or by email to [email protected].
On April 16, 2019, the Company was ordered by the U.S. Food and Drug
Administration (“FDA”) to stop selling and distributing its surgical
mesh products. According to the FDA, the Company had “not demonstrated a
reasonable assurance of safety and effectiveness for these devices.”
On this news, the Company’s share price fell $2.90 per share, more than
7%, over the following two trading sessions to close at $34.91 per share
on April 17, 2019, thereby injuring investors.
The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Boston Scientific’s
surgical mesh products indicated for the transvaginal repair of POP were
unsafe; (2) accordingly, Boston Scientific’s continued marketing and
sales of these devices in the United States was unlikely to be
sustainable; (3) separately, the Company had sold vaginal mesh implants
containing counterfeit or adulterated resin products imported from
China; (4) the foregoing conduct subjected the Company to a heightened
risk of regulatory scrutiny and/or government investigations; and (5) as
a result, the Company’s public statements were materially false and
misleading at all relevant times.
If you purchased shares of Boston Scientific during the Class Period you
may move the Court no later than June 24, 2019 to ask
the Court to appoint you as lead plaintiff if you meet certain legal
requirements. To be a member of the class action you need not take any
action at this time; you may retain counsel of your choice or take no
action and remain an absent member of the class action. If you wish
to learn more about this class action, or if you have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Howard G. Smith, Esquire, of Law Offices
of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania
19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by
email to [email protected],
or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com
